about
Pharmacological management of IPFIntensive chemotherapy regimen (LMB86) for St Jude stage IV AIDS-related Burkitt lymphoma/leukemia: a prospective study.Severe hematologic complications after lung transplantation in patients with telomerase complex mutations.Granulomatous disease in CVID: retrospective analysis of clinical characteristics and treatment efficacy in a cohort of 59 patients.Detection of alveolar fibrocytes in idiopathic pulmonary fibrosis and systemic sclerosisThe MUC5B variant is associated with idiopathic pulmonary fibrosis but not with systemic sclerosis interstitial lung disease in the European Caucasian populationHeterozygous RTEL1 mutations are associated with familial pulmonary fibrosis.Different KCO and VA combinations exist for the same DLCO value in patients with diffuse parenchymal lung diseases.Membrane-anchored Serine Protease Matriptase Is a Trigger of Pulmonary Fibrogenesis.Familial forms of nonspecific interstitial pneumonia/idiopathic pulmonary fibrosis: clinical course and genetic background.Pulmonary manifestations of human herpesvirus-8 during HIV infection.Familial pulmonary fibrosis.Investigation of Lung Involvement in Connective Tissue Disorders.Pulmonary mucosa-associated lymphoid tissue lymphoma revisited.Shrinking lung syndrome associated with systemic lupus erythematosus: A multicenter collaborative study of 15 new cases and a review of the 155 cases in the literature focusing on treatment response and long-term outcomes.Combined pulmonary fibrosis and emphysema: The many aspects of a cohabitation contract.Lymphoproliferative Disorders of the Lung.Germline SFTPA1 mutation in familial idiopathic interstitial pneumonia and lung cancer.Lung cancer in combined pulmonary fibrosis and emphysema: a series of 47 Western patients.[Pulmonary involvement due to HHV-8 virus during the course of HIV infection].Good syndrome: an adult-onset immunodeficiency remarkable for its high incidence of invasive infections and autoimmune complications.Pulmonary manifestations in adult patients with chronic granulomatous disease.Monoclonal Anti-TNF-α Antibodies for Severe Steroid-Dependent Asthma: A Case Series.Distinguishing the histological and radiological features of cystic lung disease in Birt-Hogg-Dubé syndrome from those of tobacco-related spontaneous pneumothorax.Activation of somatostatin receptors attenuates pulmonary fibrosis.Clinical characteristics and prognostic factors of pulmonary MALT lymphoma.Modulation of bleomycin-induced lung fibrosis by serotonin receptor antagonists in mice.Rituximab therapy in autoimmune pulmonary alveolar proteinosis.Prevalence and characteristics of TERT and TERC mutations in suspected genetic pulmonary fibrosis.Airway-Centered Fibroelastosis: A Distinct Entity.Increased volume of conducting airways in idiopathic pulmonary fibrosis is independent of disease severity: a volumetric capnography study.FGF9 and FGF18 in idiopathic pulmonary fibrosis promote survival and migration and inhibit myofibroblast differentiation of human lung fibroblasts in vitro.Interstitial lung disease in anti-synthetase syndrome: initial and follow-up CT findings.Pulmonary fibrosis associated with TINF2 gene mutation: is somatic reversion required?Prevalence of telomere shortening in familial and sporadic pulmonary fibrosis is increased in men.Blood stem cell transplantation to treat cystic lung light chain deposition disease.The Genetic Diagnosis of Interstitial Lung Disease: A Need for an International Consensus.Safety and efficacy of pirfenidone in patients carrying telomerase complex mutation.Treatment of neurosarcoidosis: A comparative study of methotrexate and mycophenolate mofetil.Respiratory Distress, Congenital Hypothyroidism and Hypotonia in a Newborn.
P50
Q26748808-7DBE4DC7-B681-4024-A5C0-67933AFFF375Q33289847-5DFE6D59-F8A9-4435-B22C-56A30B03C7AFQ33419942-B350F749-56A5-4E46-94A0-5E9ADDB4514FQ34300297-9241D272-D916-4903-AEB4-AD7BF34030C3Q34558662-C565E43B-362E-40BE-AD88-50DF82BC878AQ34935466-FE684B8C-5083-4F39-B41D-B81DA35007A2Q35645765-E677DE08-A6F7-469A-B25B-534197135D68Q35763053-7652197F-A7FD-4391-98C7-81A772A6AE4FQ36847591-4329A289-33AF-4071-BEFA-DE1536056D95Q38025236-77C072F2-163E-40B5-AEEE-7F1A98191E82Q38080469-A7A585C0-3B16-42FC-9F18-649C0592B6A3Q38321908-610E4E4A-E1F2-4E72-9D6A-49F84CC59EC2Q38542162-B36E79C1-F056-4FFE-8ADA-B0CBDA5FDAC0Q38706895-A57F28C4-92DA-4A8B-B02C-7973A1A6638BQ38915450-95F0520A-0F41-4177-BFB9-F0532B252F5AQ38919001-A56FAFA6-3382-4287-A09C-82D53C79DBBEQ39369904-69AD1C42-4BE7-498C-9100-938536F3F8A8Q40081417-91F272F5-4A72-418E-BC6A-01A549A6CF7BQ40217670-59A66F8E-BA61-42B9-BF3B-63C924E81275Q40264892-D3D92F08-82F7-4C21-86E0-1AAF81E7CB7DQ41365452-616BA2D8-ECE3-485E-AC3B-DC7C98D3D7D4Q41525932-6576FA59-7906-4333-9E98-7C06E5AB7EC4Q41823738-EDC1933E-96C0-4FB5-93FC-902D48B5549BQ42447325-E5F42B14-49F0-4CDB-ABFF-48A9E381D311Q42520503-CF74AC16-D8D1-49B1-BEB3-7DB39315E79BQ45420908-D7315C38-B750-419D-91C8-CE65A2AF6C80Q46717257-2C27572F-A7AA-4A4B-9984-478E8766CE3AQ47686970-6B0DFE35-5A64-47F7-A96D-D21FFC33F223Q47699201-60B99316-0193-43A4-972C-DDDC32BC9BA3Q47716643-06D7B3C1-695C-4188-8737-39F05123BEA1Q47716772-B6ACA3BA-F6FF-4BF9-9CC2-A37FA53B800AQ47717645-99D84F4C-0728-48A7-B3FD-FB3CD18C7DB7Q47736894-2B67DBE1-5DBD-46FB-BA28-FAE307760C80Q47745488-473368F2-52D2-4460-BD81-042205AE460DQ47755702-D843FD9F-F23E-45C3-A966-DD3EEC61E3D7Q48160242-9578F9B6-6C92-4FA5-89C1-5519B9CFC8A1Q48344773-EAECBEFE-F638-43F2-A30A-0C2DC4268633Q49960065-3471367D-A5AC-4C7C-9B53-21312605ACA9Q51062413-C57B2F32-82DE-40A8-81DD-45733631B845Q51460614-552BE36A-D4F2-48BB-A249-817049987544
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Raphael Borie
@ast
Raphael Borie
@en
Raphael Borie
@es
Raphael Borie
@sl
type
label
Raphael Borie
@ast
Raphael Borie
@en
Raphael Borie
@es
Raphael Borie
@sl
prefLabel
Raphael Borie
@ast
Raphael Borie
@en
Raphael Borie
@es
Raphael Borie
@sl
P106
P21
P31
P496
0000-0002-9906-0024